Sign in Sign up for free

Last updated: 8 November 2021 at 4:55pm EST

Andrew Einhorn Net Worth



Andrew Einhorn biography

Andrew Einhorn serves as Chief Financial Officer of the Company. Mr. Einhorn has more than 15 years of experience in the pharmaceutical industry. From March 2014 to March 2017, Mr. Einhorn served as the Chief Financial Officer of Edge Therapeutics, Inc., a clinical-stage biotechnology company that he joined as Executive Vice President of Corporate Development in May 2013. Prior to that, he was a co-founder, Executive Vice President and Chief Financial Officer at Oceana Therapeutics, Inc. from May 2008 to January 2012. Previously, Mr. Einhorn was a co-founder and Chief Financial Officer of both Esprit Pharma, Inc., from June 2005 to October 2007, and ESP Pharma, Inc., from April 2003 to March 2005. From 1983 to 2003, Mr. Einhorn was an investment banker with Credit Lyonnais Securities, PNC Capital Markets, Chase Securities, Inc., Bankers Trust Company and the Chase Manhattan Bank. Mr. Einhorn is licensed as a Certified Public Accountant in the State of New Jersey and holds a B.S. in Finance and Accounting from The American University.

What is the salary of Andrew Einhorn?

As the Chief Financial Officer of Osmotica Pharmaceuticals Plc, the total compensation of Andrew Einhorn at Osmotica Pharmaceuticals Plc is $505,072. There are 8 executives at Osmotica Pharmaceuticals Plc getting paid more, with Brian Markison having the highest compensation of $4,338,620.



How old is Andrew Einhorn?

Andrew Einhorn is 60, he's been the Chief Financial Officer of Osmotica Pharmaceuticals Plc since 2017. There are 5 older and 9 younger executives at Osmotica Pharmaceuticals Plc. The oldest executive at Osmotica Pharmaceuticals Plc is Fred Weiss, 78, who is the Independent Director.

What's Andrew Einhorn's mailing address?

Andrew's mailing address filed with the SEC is C/O OSMOTICA PHARMACEUTICALS PLC, 400 CROSSING BOULEVARD, BRIDGEWATER, NJ, 08807.

Insiders trading at Osmotica Pharmaceuticals Plc

Over the last 6 years, insiders at Osmotica Pharmaceuticals Plc have traded over $0 worth of Osmotica Pharmaceuticals Plc stock and bought 6,343,800 units worth $31,350,366 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman, and Ltd Orbit Co Invest A 1 Llc.... On average, Osmotica Pharmaceuticals Plc executives and independent directors trade stock every 117 days with the average trade being worth of $1,173,603. The most recent stock trade was executed by James Schaub on 16 December 2021, trading 93,800 units of OSMT stock currently worth $100,366.



What does Osmotica Pharmaceuticals Plc do?

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.



What does Osmotica Pharmaceuticals Plc's logo look like?

Osmotica Pharmaceuticals Plc logo

Osmotica Pharmaceuticals Plc executives and stock owners

Osmotica Pharmaceuticals Plc executives and other stock owners filed with the SEC include: